Aromatase inhibitors in the treatment of short stature

Endocrine Development

Volumn 30, Issue , 2016, Pages 130-140

  Hero, Matti ^a  

^a UNIVERSITY OF HELSINKI AND HELSINKI UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; AROMATASE INHIBITOR; ESTROGEN; EXEMESTANE; FADROZOLE; FORMESTANE; LETROZOLE; PLACEBO; TESTOLACTONE; TESTOSTERONE; VOROZOLE;

ADULTHOOD; BODY HEIGHT; BONE MATURATION; COGNITION; DRUG CLASSIFICATION; DRUG INDICATION; ESTROGEN SYNTHESIS; FOLLOW UP; GROWTH HORMONE DEFICIENCY; HUMAN; HYPOTHALAMUS HYPOPHYSIS GONAD SYSTEM; LABORATORY TEST; MALE; METABOLIC PARAMETERS; PHARMACODYNAMICS; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RADIOGRAPHY; REVIEW; SHORT STATURE; SPERMATOGENESIS; TREATMENT DURATION; ADOLESCENT; CHILD; DWARFISM;

ADOLESCENT; AROMATASE INHIBITORS; CHILD; DWARFISM; HUMANS; MALE;

EID: 84951158056     PISSN: 14217082     EISSN: 16622979     Source Type: Book Series    
DOI: 10.1159/000439338     Document Type: Review

References (39)

1. Bulun SE, Takayama K, Suzuki T, Sasano H, Yilmaz B, Sebastian S: Organization of the human aromatase P450 (CYP19) gene. Semin Reprod Med 2004; 22: 5-9.
2. Smith EP, Boyd J, Frank GR, Takahashi H, Cohen RM, Specker B, Williams TC, Lubahn DB, Korach KS: Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med 1994; 331: 1056-1161.
3. Morishima A, Grumbach MM, Simpson ER, Fisher C, Qin K: Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J Clin Endocrinol Metab 1995; 80: 3689-3398.
4. Carani C, Qin K, Simoni M, Faustini-Fustini M, Serpente S, Boyd J, Korach KS, Simpson ER: Effect of testosterone and estradiol in a man with aromatase deficiency. N Engl J Med 1997; 337: 91-95.
5. Wit JM, Hero M, Nunez SB: Aromatase inhibitors in pediatrics. Nat Rev Endocrinol 2011; 8: 135-147.
6. Leschek EW, Jones J, Barnes KM, Hill SC, Cutler GB Jr: Six-year results of spironolactone and testolactone treatment of familial male-limited precocious puberty with addition of deslorelin after central puberty onset. J Clin Endocrinol Metab 1999; 84: 175-118.
7. Reiter EO, Mauras N, McCormick K, Kulshreshtha B, Amrhein J, De Luca F, O'Brien S, Armstrong J, Melezinkova H: Bicalutamide plus anastrozole for the treatment of gonadotropin-independent precocious puberty in boys with testotoxicosis: a phase II, open-label pilot study (BATT). J Pediatr Endocrinol Metab 2010; 23: 999-1009.
8. Binder G, Iliev DI, Dufke A, Wabitsch M, Schweizer R, Ranke MB, Schmidt M: Dominant transmission of prepubertal gynecomastia due to serum estrone excess: hormonal, biochemical, and genetic analysis in a large kindred. J Clin Endocrinol Metab 2005; 90: 484-492.
9. Lefevre H, Bouvattier C, Lahlou N, Adamsbaum C, Bougneres P, Carel JC: Prepubertal gynecomastia in Peutz-Jeghers syndrome: incomplete penetrance in a familial case and management with an aromatase inhibitor. Eur J Endocrinol 2006; 154: 221-227.
10. Grandone A, del Giudice EM, Cirillo G, Santarpia M, Coppola F, Perrone L: Prepubertal gynecomastia in two monozygotic twins with Peutz-Jeghers syndrome: two years' treatment with anastrozole and genetic study. Horm Res Paediatr 2011; 75: 374-379.
11. Feuillan P, Calis K, Hill S, Shawker T, Robey PG, Collins MT: Letrozole treatment of precocious puberty in girls with the McCune-Albright syndrome: a pilot study. J Clin Endocrinol Metab 2007; 92: 2100-2106.
12. Mieszczak J, Lowe ES, Plourde P, Eugster EA: The aromatase inhibitor anastrozole is ineffective in the treatment of precocious puberty in girls with Mc-Cune-Albright syndrome. J Clin Endocrinol Metab 2008; 93: 2751-2754.
13. Plourde PV, Reiter EO, Jou HC, Desrochers PE, Rubin SD, Bercu BB, Diamond FB Jr, Backeljauw PF: Safety and efficacy of anastrozole for the treatment of pubertal gynecomastia: a randomized, doubleblind, placebo-controlled trial. J Clin Endocrinol Metab 2004; 89: 4428-4433.
14. Merke DP, Keil MF, Jones JV, Fields J, Hill S, Cutler GB Jr: Flutamide, testolactone, and reduced hydrocortisone dose maintain normal growth velocity and bone maturation despite elevated androgen levels in children with congenital adrenal hyperplasia. J Clin Endocrinol Metab 2000; 85: 1114-1120.
15. Santen RJ, Brodie H, Simpson ER, Siiteri PK, Brodie A: History of aromatase: saga of an important biological mediator and therapeutic target. Endocr Rev 2009; 30: 343-375.
16. Mauras N, O'Brien KO, Klein KO, Hayes V: Estrogen suppression in males: metabolic effects. J Clin Endocrinol Metab 2009; 85: 2370-2237.
17. Neely EK, Kumar RB, Payne SL, Ranadive SA, Suchet DI: Letrozole vs anastrozole for height augmentation in short pubertal males: first year data. J Clin Endocrinol Metab 2014; 99: 4086-4093.
18. Hero M, Norjavaara E, Dunkel L: Inhibition of estrogen biosynthesis with a potent aromatase inhibitor increases predicted adult height in boys with idiopathic short stature: a randomized controlled trial. J Clin Endocrinol Metab 2005; 90: 6396-6402.
19. Wickman S, Sipila I, Ankarberg-Lindgren C, Norjavaara E, Dunkel L: A specific aromatase inhibitor and potential increase in adult height in boys with delayed puberty: a randomised controlled trial. Lancet 2001; 357: 1743-1178.
20. Salehpour S, Alipour P, Razzaghy-Azar M, Ardeshirpour L, Shamshiri A, Monfared MF, Gharib A: A double-blind, placebo-controlled comparison of letrozole to oxandrolone effects upon growth and puberty of children with constitutional delay of puberty and idiopathic short stature. Horm Res Paediatr 2010; 74: 428-435.
21. Mauras N, Gonzalez de Pijem L, Hsiang HY, Desrosiers P, Rapaport R, Schwartz ID, Klein KO, Singh RJ, Miyamoto A, Bishop K: Anastrozole increases predicted adult height of short adolescent males treated with growth hormone: a randomized, placebo-controlled, multicenter trial for one to three years. J Clin Endocrinol Metab 2008; 93: 823-831.
22. Wickman S, Dunkel L: Inhibition of P450 aromatase enhances gonadotropin secretion in early and midpubertal boys: evidence for a pituitary site of action of endogenous E. J Clin Endocrinol Metab 2001; 86: 4887-4894.
23. Hero M, Wickman S, Hanhijarvi R, Siimes MA, Dunkel L: Pubertal upregulation of erythropoiesis in boys is determined primarily by androgen. J Pediatr 2005; 146: 245-252.
24. Hero M, Wickman S, Dunkel L: Treatment with the aromatase inhibitor letrozole during adolescence increases near-final height in boys with constitutional delay of puberty. Clin Endocrinol (Oxf) 2006; 64: 510-513.
25. Hero M, Toiviainen-Salo S, Wickman S, Makitie O, Dunkel L: Vertebral morphology in aromatase inhibitor-treated males with idiopathic short stature or constitutional delay of puberty. J Bone Miner Res 2010; 25: 1536-1543.
26. Taxel P, Kennedy DG, Fall PM, Willard AK, Clive JM, Raisz LG: The effect of aromatase inhibition on sex steroids, gonadotropins, and markers of bone turnover in older men. J Clin Endocrinol Metab 2001; 86: 2869-2874.
27. Hero M, Makitie O, Kroger H, Nousiainen E, Toiviainen-Salo S, Dunkel L: Impact of aromatase inhibitor therapy on bone turnover, cortical bone growth and vertebral morphology in pre-and peripubertal boys with idiopathic short stature. Horm Res 2009; 71: 290-297.
28. Wickman S, Saukkonen T, Dunkel L: The role of sex steroids in the regulation of insulin sensitivity and serum lipid concentrations during male puberty: a prospective study with a P450-aromatase inhibitor. Eur J Endocrinol 2002; 146: 339-346.
29. Hero M, Ankarberg-Lindgren C, Taskinen MR, Dunkel L: Blockade of oestrogen biosynthesis in peripubertal boys: effects on lipid metabolism, insulin sensitivity, and body composition. Eur J Endocrinol 2006; 155: 453-460.
30. Kampen DL, Sherwin BB: Estrogen use and verbal memory in healthy postmenopausal women. Obstet Gynecol 1994; 83: 979-983.
31. Cherrier MM, Matsumoto AM, Amory JK, Ahmed S, Bremner W, Peskind ER, Raskind MA, Johnson M, Craft S: The role of aromatization in testosterone supplementation: effects on cognition in older men. Neurology 2005; 64: 290-296.
32. Hero M, Maury S, Luotoniemi E, Service E, Dunkel L: Cognitive effects of aromatase inhibitor therapy in peripubertal boys. Eur J Endocrinol 2010; 163: 149-155.
33. Oz OK, Hirasawa G, Lawson J, Nanu L, Constantinescu A, Antich PP, Mason RP, Tsyganov E, Parkey RW, Zerwekh JE, Simpson ER: Bone phenotype of the aromatase deficient mouse. J Steroid Biochem Mol Biol 2001; 79: 49-59.
34. Shetty G, Krishnamurthy H, Krishnamurthy HN, Bhatnagar S, Moudgal RN: Effect of estrogen deprivation on the reproductive physiology of male and female primates. J Steroid Biochem Mol Biol 1997; 61: 157-166.
35. Aquila S, Sisci D, Gentile M, Carpino A, Middea E, Catalano S, Rago V, Ando S: Towards a physiological role for cytochrome P450 aromatase in ejaculated human sperm. Hum Reprod 2003; 18: 1650-1659.
36. Raman JD, Schlegel PN: Aromatase inhibitors for male infertility. J Urol 2002; 167(2 pt 1):624-629.
37. Ramasamy R, Ricci JA, Palermo GD, Gosden LV, Rosenwaks Z, Schlegel PN: Successful fertility treatment for Klinefelter's syndrome. J Urol 2009; 182: 1108-1113.
38. Mauras N, Bell J, Snow BG, Winslow KL: Sperm analysis in growth hormone-deficient adolescents previously treated with an aromatase inhibitor: comparison with normal controls. Fertil Steril 2005; 84: 239-242.
39. Geffner ME: Aromatase inhibitors to augment height: continued caution and study required. J Clin Res Pediatr Endocrinol. 2009; 1: 256-261.